Blood Advances

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease
Blood Advances - Tập 6 - Trang 5317-5326 - 2022
Ferdows Atiq, Jessica Heijdra, Fleur Snijders, Johan Boender, Eva Kempers, Waander L. van Heerde, Dominique P.M.S.M. Maas, Sandy Krouwel, Selene C. Schoormans, Joke de Meris, Saskia E.M. Schols, Karin P.M. van Galen, Johanna G. van der Bom, Marjon H. Cnossen, Karina Meijer, Karin Fijnvandraat, Jeroen Eikenboom, Frank W.G. Leebeek
Abstract Patients with type 1 and type 2 von Willebrand disease (VWD) can be treated with desmopressin. Although a previous study has shown that the location of the causative VWF gene variant is associated with desmopressin response in type 1 VWD, the association between variants in the VWF gene and desmopressin response is not yet fully understood. ...... hiện toàn bộ
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
Blood Advances - Tập 7 - Trang 414-421 - 2023
Charles T. Quinn, Richard T. Wiedmann, Daniel Jarovsky, Eduardo Lopez-Medina, Hilze M. Rodriguez, Melanie Papa, Gordana Boggio, Qiong Shou, Ron Dagan, Peter Richmond, Kristen Feemster, Richard McFetridge, Gretchen Tamms, Robert Lupinacci, Luwy Musey, Kara Bickham
AbstractSickle cell disease (SCD) is an inherited red blood cell disease that results in a multitude of medical complications, including an increased risk of invasive disease caused by encapsulated bacteria, such as Streptococcus pneumoniae. Pneumococcal vaccines have contributed to a significant reduction in pneumococcal disease (PD) in children and adults, includ...... hiện toàn bộ
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)
Blood Advances - Tập 2 - Trang 1386-1392 - 2018
Kristina Drott, Hans Hagberg, Karin Papworth, Thomas Relander, Mats Jerkeman
Key Points This trial evaluates addition of the histone deacetylase inhibitor valproate to standard R-CHOP therapy in DLBCL. Addition of valproate to R-CHOP is a promising strategy in DLBCL, but auditory side effects warrant monitoring.
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease
Blood Advances - Tập 5 - Trang 3445-3456 - 2021
Sheila K. Pierson, Sushila Shenoy, Ana B. Oromendia, Alexander M. Gorzewski, Ruth-Anne Langan Pai, Christopher Shield Nabel, Jason R. Ruth, Sophia A.T. Parente, Daniel J. Arenas, Mary Guilfoyle, Manjula Reddy, Michael Weinblatt, Nancy Shadick, Mark Bower, Alessia Dalla Pria, Yasufumi Masaki, Laura Katz, Jason Mezey, Philip Beineke, David Lee
AbstractIdiopathic multicentric Castleman disease (iMCD) is a poorly understood hematologic disorder involving cytokine-induced polyclonal lymphoproliferation, systemic inflammation, and potentially fatal multiorgan failure. Although the etiology of iMCD is unknown, interleukin-6 (IL-6) is an established disease driver in approximately one-third of patients. Anti–I...... hiện toàn bộ
Portable medical orders and end-of-life measures in acute myeloid leukemia and myelodysplastic syndromes
Blood Advances - Tập 5 - Trang 5554-5564 - 2021
Marissa LoCastro, Andrea M. Baran, Jane L. Liesveld, Eric Huselton, Michael W. Becker, Kristen Marie O'Dwyer, Omar S. Aljitawi, Megan Baumgart, Eric Snyder, Benzi Kluger, Kah Poh Loh, Jason H. Mendler
Abstract Patients with acute myeloid leukemia (AML) or a myelodysplastic syndrome (MDS) experience high rates of hospitalization, intensive care unit (ICU) admission, and in-hospital death at the end of life. Early goals-of-care (GOC) discussions may reduce the intensity of end-of-life (EOL) care. Portable Medical Order forms, known as Medical Orders...... hiện toàn bộ
Mechanistic ion channel interactions in red cells of patients with Gárdos channelopathy
Blood Advances - Tập 5 - Trang 3303-3308 - 2021
Julia Jansen, Min Qiao, Laura Hertz, Xijia Wang, Elisa Fermo, Anna Zaninoni, Raffaella Colombatti, Ingolf Bernhardt, Paola Bianchi, Lars Kaestner
Abstract In patients with Gárdos channelopathy (p.R352H), an increased concentration of intracellular Ca2+ was previously reported. This is a surprising finding because the Gárdos channel (KCa3.1) is a K+ channel. Here, we confirm the increased intracellular Ca2+ for patients with the KCa3.1 mutation p.S314P. Furthermore, we provide the concept of KC...... hiện toàn bộ
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
Blood Advances - Tập 6 - Trang 1232-1242 - 2022
Gareth P. Gregory, Shaji Kumar, Ding Wang, Daruka Mahadevan, Patricia Walker, Nina Wagner-Johnston, Carolina Escobar, Rajat Bannerji, Divaya Bhutani, Julie Chang, Francisco J. Hernandez-Ilizaliturri, Andreas Klein, John M. Pagel, Witold Rybka, Andrew J. Yee, Anne Mohrbacher, Mo Huang, Mohammed Farooqui, Patricia Marinello, Hang Quach
AbstractPreclinical data demonstrated that combining an anti–programmed cell death 1 (PD-1) inhibitor with a cyclin-dependent kinase 9 (CDK9) inhibitor provided enhanced antitumor activity with no significant toxicities, suggesting this combination may be a potential therapeutic option. The multicohort, phase 1 KEYNOTE-155 study evaluated the safety and antitumor a...... hiện toàn bộ
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
Blood Advances - Tập 4 - Trang 2245-2253 - 2020
Smith Giri, Scott F. Huntington, Rong Wang, Amer M. Zeidan, Nikolai Podoltsev, Steven D. Gore, Xiaomei Ma, Cary P. Gross, Amy J. Davidoff, Natalia Neparidze
AbstractChromosome 1 abnormalities (C1As) are common genetic aberrations among patients with multiple myeloma (MM). We aimed to evaluate the significance of C1As among a contemporary cohort of patients with MM in the United States. We used electronic health records from the Flatiron Health database to select patients newly diagnosed with MM from January 2011 to Mar...... hiện toàn bộ
Single-cell heterogeneity in Sézary syndrome
Blood Advances - Tập 2 - Trang 2115-2126 - 2018
Terkild Brink Buus, Andreas Willerslev-Olsen, Simon Fredholm, Edda Blümel, Claudia Nastasi, Maria Gluud, Tengpeng Hu, Lise M. Lindahl, Lars Iversen, Hanne Fogh, Robert Gniadecki, Ivan V. Litvinov, Jenny L. Persson, Charlotte Menné Bonefeld, Carsten Geisler, Jan Pravsgaard Christensen, Thorbjørn Krejsgaard, Thomas Litman, Anders Woetmann, Niels Ødum
Key Points Individual patients with Sézary syndrome contain several distinct malignant subpopulations and show marked single-cell heterogeneity. Malignant subpopulations exhibit differences in their sensitivity to treatment warranting precision therapy.
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
Blood Advances - Tập 7 - Trang 5272-5280 - 2023
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John Kuruvilla, David Cunningham, Justin Kline, Nathalie A. Johnson, Neha Mehta-Shah, Julie Lisano, Rachael Wen, Alev Akyol, Alison J. Moskowitz
Abstract Patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL) have poor responses to salvage therapy. Nivolumab and brentuximab vedotin (BV) showed promising early efficacy in patients with R/R PMBL in the phase 1/2 open-label, multicenter CheckMate 436 study; we report safety and efficacy findings from the 3-year fo...... hiện toàn bộ
Tổng số: 1,527   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10